Clinical Management of HIV Drug Resistance

被引:55
作者
Cortez, Karoll J. [1 ]
Maldarelli, Frank [1 ]
机构
[1] NCI, HIV Drug Resistance Program, NIH, Bethesda, MD 20892 USA
来源
VIRUSES-BASEL | 2011年 / 3卷 / 04期
关键词
HIV; drug resistance testing; clinical management; IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE INHIBITORS; NON-B SUBTYPES; SUSTAINED VIROLOGICAL SUPPRESSION; TREATMENT-EXPERIENCED PATIENTS; RANDOMIZED CONTROLLED-TRIAL; TREATMENT-NAIVE PATIENTS; SINGLE-DOSE NEVIRAPINE; ROCHE COBAS AMPLICOR;
D O I
10.3390/v3040347
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Combination antiretroviral therapy for HIV-1 infection has resulted in profound reductions in viremia and is associated with marked improvements in morbidity and mortality. Therapy is not curative, however, and prolonged therapy is complicated by drug toxicity and the emergence of drug resistance. Management of clinical drug resistance requires in depth evaluation, and includes extensive history, physical examination and laboratory studies. Appropriate use of resistance testing provides valuable information useful in constructing regimens for treatment-experienced individuals with viremia during therapy. This review outlines the emergence of drug resistance in vivo, and describes clinical evaluation and therapeutic options of the individual with rebound viremia during therapy.
引用
收藏
页码:347 / 378
页数:32
相关论文
共 176 条
[1]   PRODUCTION OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED RETROVIRUS IN HUMAN AND NONHUMAN CELLS TRANSFECTED WITH AN INFECTIOUS MOLECULAR CLONE [J].
ADACHI, A ;
GENDELMAN, HE ;
KOENIG, S ;
FOLKS, T ;
WILLEY, R ;
RABSON, A ;
MARTIN, MA .
JOURNAL OF VIROLOGY, 1986, 59 (02) :284-291
[2]   Pharmacogenetics of cutaneous adverse drug reactions [J].
Aihara, Michiko .
JOURNAL OF DERMATOLOGY, 2011, 38 (03) :246-254
[3]  
Altmann A, 2009, ANTIVIR THER, V14, P273
[4]   The Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutation I132M Confers Hypersensitivity to Nucleoside Analogs [J].
Ambrose, Zandrea ;
Herman, Brian D. ;
Sheen, Chih-Wei ;
Zelina, Shannon ;
Moore, Katie L. ;
Tachedjian, Gilda ;
Nissley, Dwight V. ;
Sluis-Cremer, Nicolas .
JOURNAL OF VIROLOGY, 2009, 83 (08) :3826-3833
[5]  
Anderson Jeffrey, 2009, V189, P85
[6]  
[Anonymous], HIV FRENCH RESISTANC
[7]  
[Anonymous], 2009, A guide for schools and communities, P1
[8]  
[Anonymous], HIV DRUG RESISTANCE
[9]   Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing [J].
Archer, John ;
Braverman, Michael S. ;
Taillon, Bruce E. ;
Desany, Brian ;
James, Ian ;
Harrigan, P. Richard ;
Lewis, Marilyn ;
Robertson, David L. .
AIDS, 2009, 23 (10) :1209-1218
[10]   The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml [J].
Arribas, Jose R. ;
Horban, Andrzej ;
Gerstoft, Jan ;
Faetkenheuer, Gerdt ;
Nelson, Mark ;
Clumeck, Nathan ;
Pulido, Federico ;
Hill, Andrew ;
van Delft, Yvon ;
Stark, Thomas ;
Moecklinghoff, Christiane .
AIDS, 2010, 24 (02) :223-230